Maurice was halfway through a banana split when he noticed the da Vinci robot had company—and he didn’t look happy about it.
There’s a moment in every dominant company’s life where you have to ask yourself a hard question: Is this still the king of the jungle, or just the biggest chimp in a shrinking territory?
That question is exactly what I’ve been wrestling with regarding Intuitive Surgical (ISRG), the $168 billion medical robotics titan that’s spent nearly three decades owning minimally invasive surgery like I own bananas. The da Vinci Surgical System is genuinely revolutionary—a piece of technology that transformed how surgeons work and how hospitals generate revenue. But here’s the thing that’s been nagging at me: the game is changing, and not everyone’s playing by da Vinci’s rules anymore.
Let me paint the picture. Intuitive trades at a 57.5x P/E ratio. That’s not a typo. We’re talking about a company priced like it’s going to cure cancer, eradicate malaria, and teach bananas to perform their own surgeries. The forward P/E is friendlier at 40x, but still—that’s the valuation of a company that better be executing flawlessly while simultaneously inventing the future.
And here’s where I had to put down my banana and actually think.
The Dominance That Got Them Here
First, let’s be fair to Intuitive. They didn’t become a $168 billion company by accident. The da Vinci system is genuinely incredible. Surgeons control a robot from a console, performing procedures with precision that human hands alone can’t match. Over the past decade, hospitals have been installing these things like they’re going out of style—because minimally invasive surgery is objectively better for patients. Smaller incisions. Less pain. Faster recovery. Insurance companies love it. Patients love it. Surgeons love it.
The financials reflect that dominance. Revenue growth of 23% year-over-year is nothing to sneeze at. Earnings growth of 18.8%. A profit margin of 28%. Free cash flow of $2.25 billion. This is a company that prints money like I print banana peels. The installed base of da Vinci systems keeps growing. Hospitals are locked in—they’ve invested millions in equipment, trained their surgeons, integrated the systems into their surgical workflows. That’s a moat, and it’s real.
And the expansion opportunities genuinely exist. Intuitive’s Ion endoluminal system is expanding their addressable market beyond surgical procedures into diagnostic work. That’s smart diversification. The recurring revenue from instruments and maintenance creates predictable cash flows. Wall Street loves this stock for good reasons—30 analysts covering it, most with buy ratings, and a median price target of $577 (compared to the current $475) suggests another 22% upside.
But—and this is a very important “but” that’s been bothering me like a monkey with an unpeeled banana—valuation and competition are starting to look like twin storm clouds.
The Crowd Is Growing, And It’s Hungry
Here’s what nobody wants to admit at cocktail parties: Intuitive doesn’t own surgery anymore. Not really.
Johnson & Johnson just landed CE mark approval for the Ottava surgical system. That’s a robot designed to compete directly with da Vinci. Stryker is building surgical robotics platforms. Karl Storz is developing autonomous surgical technology. CMR Surgical, a UK company, has been aggressively expanding Versius, a modular robotic system designed to be more portable and cost-effective than da Vinci. These aren’t theoretical competitors. These are real companies with real capital, real experience in healthcare, and real determination to carve out market share.
What’s particularly interesting—and what Wall Street seems to be glossing over—is that these newer systems are designed to be cheaper, more flexible, and easier to integrate into hospital workflows. Da Vinci is a Rolls-Royce. These new systems are trying to be the Honda Civic: reliable, affordable, and available in every city. That’s a dangerous position for a premium-priced market leader to be in.
Think of it like this: Imagine bananas had been the only fruit in the produce aisle for 25 years. Hospitals got used to bananas. They built their entire supply chain around bananas. They trained their staff on bananas. They made money with bananas. But now oranges, apples, and grapes are showing up with better shelf stability, lower prices, and celebrity endorsements. The banana is still good—still the highest quality—but suddenly it’s not the only option. And in healthcare, choice matters because margins matter.
Now, I should note that the recall issues mentioned in some recent coverage—particularly around da Vinci stapler reliability—are a warning sign, not a death knell. Medical device companies deal with recalls. But they’re a reminder that even market leaders aren’t immune to execution risk. And when you’re priced at 57x earnings, execution has to be literally perfect.
The Valuation Paradox
This is where I have to be honest about what’s really bothering me. ISRG is a phenomenal company. But it’s trading like a phenomenal company that’s also immune to competition and immortal.
A 57.5x trailing P/E and 40x forward P/E assumes:
—Sustained high-double-digit revenue growth for many years. Possible? Yes. Guaranteed? Absolutely not. As the installed base grows and the market matures, growth inevitably decelerates.
—Maintained pricing power despite increasing competition. This is where I get skeptical. Surgical robots are complex, but they’re not getting less complex over time for competitors to build. The gap between the da Vinci and next-generation competitors will narrow. Hospitals will have leverage to negotiate price.
—No major technological disruption. What if AI-assisted surgery, augmented reality guidance systems, or some hybrid approach that doesn’t require a $2+ million up-front capital investment becomes the standard? Da Vinci has been the gold standard so long that people assume it always will be. History suggests otherwise.
—Macro stability. Here’s a macro risk nobody’s talking about: Healthcare spending is under intense pressure globally. Insurance companies are fighting hospital margins. Governments are restricting medical device pricing. In Europe, pressure on healthcare budgets could slow adoption of premium-priced robotics. In the US, if there’s any shift toward value-based care or if hospital margins compress further, capital equipment spending gets cut first and fastest. Intuitive’s growth could look very different in a recessionary environment.
The PEG ratio of 2.59 is telling. That’s actually not terrible (below 3 is generally considered reasonable for growth stocks), but it’s a yellow light. The stock has already rallied from $427 to $475 (and was at $603 just 52 weeks ago). It’s up significantly, and much of the good news appears priced in.
The Beta Problem Nobody Mentions
ISRG has a beta of 1.679. That means it’s nearly 70% more volatile than the broader market. In a tech correction, surgical robotics stocks don’t hold up well because they’re still perceived as “growth” rather than “healthcare essential.” If we get a market pullback—and let’s be honest, we’re due—ISRG could see 15-25% downside before you could say “minimally invasive.”
The short ratio of 4.03% suggests some bearish positioning, but not enough to indicate extreme pessimism. That’s actually normal for a mega-cap stock. It’s not a red flag, but it’s also not a vote of confidence from smart money.
What Could Go Right (And Right Now, It’s Priced In)
Look, I’m not here to tell you Intuitive is going to zero. That’s absurd. The company is profitable, growing, and operating in a sector with genuine tailwinds. Aging populations need more surgery. Minimally invasive techniques are becoming standard of care. Hospital margins are improving in pockets. The Ion system could be genuinely transformative if adoption accelerates. International expansion—particularly in Asia where they’re less entrenched—could drive meaningful growth.
And yes, Wall Street’s buy ratings and $577 target price suggest another 22% upside. That’s not nothing. But here’s the thing: that upside is contingent on near-perfect execution in an increasingly competitive environment, while valued at a premium that assumes exactly that.
The Verdict: A Watch, Not a Buy
I’m rating Intuitive Surgical a 6.7 on the Monkey Momentum Index. Here’s why I’m not higher:
This is a great company. But “great company” doesn’t automatically equal “good buy.” The valuation has stretched ahead of fundamentals. Competition is accelerating, not decelerating. Macro headwinds in healthcare spending are real. The stock has already had a significant run, and most of the obvious upside appears priced in.
That doesn’t mean sell it if you own it. If you’re a long-term investor with a 5-10 year horizon and believe in minimally invasive surgery dominance, ISRG will probably be fine. But at current prices, I’m not convinced the risk-reward justifies the premium.
I’d much rather buy this stock at $420 (a 12% pullback) than chase it higher from here. And I’d absolutely be adding if it corrected to $380-400 in a broader market pullback. That’s where the real opportunity lives—not in the premium valuation today.
The banana is still the best fruit in the bowl. But the bowl is getting crowded, and premium prices are only justified when you own the bowl. Right now, Intuitive owns most of the bowl—but “most” is starting to matter in a way it didn’t five years ago.
Maurice threw a banana peel at his monitor, adjusted his tie, and made a note: “Wait for the dip. Good companies, fairly priced. Great companies at premium prices are just expensive good companies with extra steps.”
Trained Market Monkey 